Prosecution Insights
Last updated: July 17, 2026
Application No. 18/567,687

O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS

Non-Final OA §112
Filed
Dec 06, 2023
Priority
Jun 11, 2021 — provisional 63/209,555 +3 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Glaxosmithkline Intellectual Property (No 4) Limited
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
837 granted / 1032 resolved
+21.1% vs TC avg
Moderate +9% lift
Without
With
+9.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
67 currently pending
Career history
1087
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
21.7%
-18.3% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
33.4%
-6.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1032 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of group I in the reply filed on 2026 April 30 is acknowledged. A search has been conducted against the entirety of claim 1 due to no prior art against the elected species. Claims 1, 4, 6, 9, 12, 13, 17, 19, 23, 25, 28, 35, 43, 46, 51, 60-62, and 67 are examined on the merits. Claims 64 and 66 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 2026 April 30. Information Disclosure Statement The information disclosure statements (IDS) submitted on 2023 December 6, 2025 December 18, and 2026 April 29 were submitted in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 60 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The compounds of tables 1, 2, and 3 of the specification should be recited within the claim. See MPEP 2173.05(s). Due the specification being amendable, the scope of the compounds of in these tables defines the metes and bounds of the claim. Conclusion Claims 1, 4, 6, 9, 12, 13, 17, 19, 23, 25, 28, 35, 43, 46, 51, 61, 62, and 67 are allowed. Claim 60 is not allowable. The following is a statement of reasons for the indication of allowable subject matter: BARSANTI (WO 2022/118210, published 2022 June 9, cited in IDS) describes compound 1 (page 47), which does not anticipate or render obvious a compound of claim 1 because an alkyl group of R3 cannot be substituted by a pyran ring. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Dec 06, 2023
Application Filed
Jul 10, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679841
PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
4y 7m to grant Granted Jul 14, 2026
Patent 12679858
METAL IRIDIUM COMPLEX AND USE THEREOF
3y 7m to grant Granted Jul 14, 2026
Patent 12679818
RADIOACTIVE HALOGEN LABELING PRECURSOR COMPOUND
3y 2m to grant Granted Jul 14, 2026
Patent 12679825
CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR
3y 2m to grant Granted Jul 14, 2026
Patent 12668593
PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 5m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+9.3%)
2y 11m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1032 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month